Xenovaccinotherapy for Cancer

Селедцов, В. И.; Shishkov, Alexey A.; Селедцова, Г. В.

doi:10.5772/23671

Cited by 5 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, has shown the development of prolonged anticancer response in mice with melanoma В-16 vaccinated with human melanoma cells SK-MEL-1 at the background of increased CTL activity. Activation of specific chain of cell immunity has been also documented in clinical studies when the patients with uveal melanoma were vaccinated with xenogeneic vaccine containing mouse melanoma В-16 cells transplanted into conjunctive tissue capsule [17,18], or when the patients with metastatic skin melanoma were vaccinated with polyantigen cellular vaccine on the basis of В-16 melanoma cells and mouse Lewis lung carcinoma cells [16]. Antimetastatic efficacy of xenogeneic anticancer vaccine developed on the basis of embryonal proteins and products of bacterial origin (B. subtilis) is mostly exerted via activation of effectors of unspecific immunity (PM and NK).…”

Section: Resultsmentioning

confidence: 99%

“…An induction of specific cellular and humoral immune response against self tumor antigens in the case of use of xenogeneic vaccines relies on high homology between tumor-associated antigens of man and animals [10][11][12], in particular those of man and mouse [13,14]. The presence of such homology was utilized in some experimental and clinical stu dies where for melanoma treatment tumor antigens of mouse were used as xenogeneic ones in humans, and vice versa [15,16]. In particular, xenovaccination with the use of transplantable human melanoma SK-MEL-28 cells or primary human melanoma cell culture performed at prophylactic regimen with following removal of primary tumor node, resulted in significant suppression of syngeneic melanoma В-16 in mice and reduced lung metastasis.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Cytotoxic Activity of Immune Cells Following Administration of Xenogeneic Cancer Vaccine in Mice With Melanoma B-16

Fedosova¹,

Voeykova²,

Karaman³

et al. 2015

Exp. Onc.

View full text Add to dashboard Cite

Aim: To study the effects of xenogeneic cancer vaccine (XCV) developed on the basis of nervous tissue antigen from rat embryo of late gestation period and protein-containing metabolite of Bacillus subtilis with molecular weight of 70 kDa, on specific and unspecific antitumor reactions of cellular and humoral chains of immune system, and to analyze possible mechanisms of its antimetastatic action. Materials and Methods: XCV was administered triply with 3-day intervals after surgical removal of experimental melanoma В-16 in C57Bl/6 mice. Cytotoxic activity (CTA) of splenocytes against target cells К-562 as well as CTA of splenocytes, peritoneal macrophages (PM) and blood serum against melanoma В-16 target cells were determined using МТТ test. The content of circulating immune complexes (CIC) in blood serum was evaluated by precipitation reaction. Results: Immunologic effects of XCV vaccination in experimental animals with surgically removed melanoma B-16 in comparison with similarly treated unvaccinated mice were as follows: prevention of medium molecular weight CIC accumulation in blood serum during all observation period, significant increase (р < 0.05) of CTA of effectors of unspecific antitumor immunity (natural killer cells — NK — by 25.5 ± 1.7 vs 12.5 ± 5.4%, and PM — by 37.3 ± 0.6 vs 32.0 ± 0.9%, respectively) at 37th day after the surgery, and also preservation of functional activity of specific cytotoxic lymphocytes at the level of intact control. Conclusion: The results of the study allow propose that antimetastatic effect of XCV vaccination could be based on increased CTA of NK and PM, and preservation of CTL functional activity at late terms after surgical removal of B-16 primary tumors.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Cytotoxic Activity of Immune Cells Following Administration of Xenogeneic Cancer Vaccine in Mice With Melanoma B-16

Fedosova¹,

Voeykova²,

Karaman³

et al. 2015

Exp. Onc.

View full text Add to dashboard Cite

show abstract

“…Some XAV successfully passed I-II phases of clinical trials. Their safety and ability to induce immune response without autoimmune complications have been proven [4][5][6][7][8]. Among others, genes and proteins of chicken origin which share homology with human counterparts are exploited in the XAV construction [9][10][11][12][13][14].…”

mentioning

confidence: 99%

Anticancer Effectiveness of Vaccination Based on Xenogeneic Embryo Proteins Applied in Different Schedules

et al. 2015

Exp. Onc.

View full text Add to dashboard Cite

The aim: To evaluate anticancer activity of vaccination with chicken embryo proteins (CEP) applied in different schedules. Materials and Methods: C57Bl mice were vaccinated with CEP before (prophylactic schedule) or after (different therapeutic schedules with or without preliminary tumor removal) the Lewis lung carcinoma cells transplantation. The latent period of tumor development, tumor volume and metastasis rate were evaluated. Results: Potent antimetastatic effect of CEP-based vaccination was seen in case of therapeutic regimen after primary tumor removal. The metastasis inhibition index (MII) reached 96.9 and 97.8% on 18th and 34th day after tumor removal, respectively. When CEP vaccination was performed in the settings of therapeutic regimen without primary tumor removal the anticancer effect was evident only if vaccinations started as early as 24 h after the cancer cells injections. The highest MII achieved in such condition was 77.6%, tumor volume in the group of vaccinated animals was by 53.1–42.1% lower than in the control tumor-bearing mice. CEP vaccination before tumor challenge (prophylactic immunization) led to a statistically significant prolongation of the latent period of tumor development, a reduction of tumor volume (35.8–48.8% compared to control unvaccinated mice) and a marked inhibition of metastasis (MII was 71.1%). Conclusion: Vaccination based on CEP exhibited both prophylactic and therapeutic anticancer effects. The last one is more pronounced when the vaccination starts shortly after the primary tumor resection.

show abstract

Clinically feasible and prospective immunotherapeutic interventions in multidirectional comprehensive treatment of cancer

Селедцов

Delwig

2020

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Xenovaccinotherapy for Cancer

Cited by 5 publications

References 40 publications

Cytotoxic Activity of Immune Cells Following Administration of Xenogeneic Cancer Vaccine in Mice With Melanoma B-16

Cytotoxic Activity of Immune Cells Following Administration of Xenogeneic Cancer Vaccine in Mice With Melanoma B-16

Anticancer Effectiveness of Vaccination Based on Xenogeneic Embryo Proteins Applied in Different Schedules

Clinically feasible and prospective immunotherapeutic interventions in multidirectional comprehensive treatment of cancer

Contact Info

Product

Resources

About